Page 102 - 202018
P. 102

2017,19(12):1586-1596.                              served ejection fraction[J]. N Engl J Med,2019,381(17):
        [ 4 ]  BUTLER J,FONAROW GC,ZILE MR,et al. Develop-       1609-1620.
             ing therapies for heart failure with preserved ejection frac-  [15]  王华,梁延春.中国心力衰竭诊断和治疗指南 2018[J].中
             tion:current state and future directions[J]. JACC Heart  华心血管病杂志,2018,46(10):760-789.
             Fail,2014,2(2):97-112.                         [16]  HIGGINS JP,ALTMAN DG,GØTZSCHE PC,et al. The
        [ 5 ]  GHEORGHIADE M,LARSON CJ,SHAH SJ,et al. De-        cochrane collaboration’s tool for assessing risk of bias in
             veloping new treatments for heart failure:focus on the  randomised trials[J]. BMJ,2011. DOI:10.1136/bmj.d5928.
             heart[J]. Circ Heart Fail,2016. DOI:10.1161/CIRCHE-  [17]  TUMASYAN LL,ADAMYAN K,CHILINGARYAN A,
             ARTFAILURE.115.002727.                              et al. Comparative efficacy of renin-angiotensin aldester-
        [ 6 ]  MASSIE BM,CARSON PE,MCMURRAY JJ,et al. Irbe-      on system modulators and angiotensin receptor neprilyzin
             sartan in patients with heart failure and preserved ejection  inhibitor in chronic heart failure with mid-ranged and pre-
             fraction[J]. N Engl J Med,2008,359(23):2456-2467.   served ejection fraction[J]. Eur J Heart Fail,2019. DOI:
        [ 7 ]  PONIKOWSKI P,VOORS AA,ANKER SD,et al. 2016        10.1002/ejhf.1488.
             ESC guidelines for the diagnosis and treatment of acute  [18]  王国坤.沙库巴曲缬沙坦钠片对射血分数中间值心力衰
             and chronic heart failure:the task force for the diagnosis  竭患者疗效及预后的影响分析[J].海峡药学,2019,31
             and treatment of acute and chronic heart failure of the Eu-  (11):176-177.
             ropean Society of Cardiology(ESC)developed with the  [19]  石宇杰,王剑飞,韩运峰,等.沙库巴曲缬沙坦治疗射血分
             special contribution of the Heart Failure Association  数保留心功能衰竭的疗效研究[J].中国循证心血管医学
             (HFA)of the ESC[J]. Eur Heart J,2016,37(27):        杂志,2020,12(1):83-86.
             2129-2200.                                     [20]  陈存芳,贾博,江珊,等.沙库巴曲缬沙坦对射血分数中间
        [ 8 ]  HERNANDEZ AF,HAMMILL BG,O’CONNOR CM,              值心力衰竭患者疗效及预后的分析[J].中国新药与临床
             et al. Clinical effectiveness of beta-blockers in heart fail-  杂志,2020,39(2):88-92.
             ure:findings from the optimize-HF(organized program to  [21]  ZILE MR,BAICU CF,GAASCH WH. Diastolic heart
             initiate lifesaving treatment in hospitalized patients with  failure:abnormalities in active relaxation and passive stiff-
             heart failure)registry[J]. J Am Coll Cardiol,2009,53(2):  ness of the left ventricle[J]. N Engl J Med,2004,350(19):
             184-192.                                            1953-1959.
        [ 9 ]  KOSMALA W,ROJEK A,PRZEWLOCKA-KOSMALA         [22]  KRAIGHER-KRAINER E,SHAH AM,GUPTA DK,et al.
             M,et al. Effect of aldosterone antagonism on exercise tol-  Impaired systolic function by strain imaging in heart fail-
             erance in heart failure with preserved ejection fraction[J].  ure with preserved ejection fraction[J]. J Am Coll Cardiol,
             J Am Coll Cardiol,2016,68(17):1823-1834.            2014,63(5):447-456.
        [10]  KHAN MS,FONAROW GC,KHAN H,et al. Renin-an-    [23]  MCKIE PM,SCHIRGER JA,COSTELLO-BOERRIG-
             giotensin blockade in heart failure with preserved ejection  TER LC,et al. Impaired natriuretic and renal endocrine re-
             fraction:a systematic review and meta-analysis[J]. ESC  sponse to acute volume expansion in pre-clinical systolic
             Heart Fail,2017,4(4):402-408.                       and diastolic dysfunction[J]. J Am Coll Cardiol,2011,58
        [11]  JHUND PS,MCMURRAY JJV. The neprilysin pathway in  (20):2095-2103.
             heart failure:a review and guide on the use of sacubitril/  [24]  GARDNER DG,CHEN S,GLENN DJ,et al. Molecular
             valsartan[J]. Heart,2016,102(17):1342-1347.         biology of the natriuretic peptide system:Implications for
        [12]  CAMPBELL DJ. Long-term neprilysin inhibition-impli-  physiology and hypertension[J]. Hypertension,2007,49
             cations for ARNIs[J]. Nat Rev Cardiol,2017,14(3):  (3):419-426.
             171-186.                                       [25]  DANIELS LB,MAISEL AS. Natriuretic peptides[J]. J Am
        [13]  SOLOMON SD,ZILE M,PIESKE B,et al. The angioten-    Coll Cardiol,2007,50(25):2357-2368.
             sin receptor neprilysin inhibitor LCZ696 in heart failure  [26]  MCMURRAY JJ,PACKER M,DESAI AS,et al. Angio-
             with preserved ejection fraction:a phase 2 double-blind  tensin-neprilysin inhibition versus enalapril in heart fail-
             randomised controlled trial[J]. Lancet,2012,380(9851):  ure[J]. N Engl J Med,2014,371(11):993-1004.
             1387-1395.                                                  (收稿日期:2020-04-22 修回日期:2020-07-30)
        [14]  SOLOMON SD,MCMURRAY JJV,ANAND IS,et al.                                            (编辑:陈 宏)
             Angiotensin-neprilysin inhibition in heart failure with pre-




        ·2268  ·  China Pharmacy 2020 Vol. 31 No. 18                                中国药房    2020年第31卷第18期
   97   98   99   100   101   102   103   104   105   106   107